Biotech Values

[biocqr]

TRIL >TRILLIUM THERAPEUTICS’ TTI-621 PROGRAM FEATURED AT THE EORTC CLTF CUTANEOUS LYMPHOMA CONFERENCE

http://trilliumtherapeutics.com/investors/news/Press-Release-Details/2017/Trillium-Therapeutics-TTI-621-Program-Featured-at-the-EORTC-CLTF-Cutaneous-Lymphoma-Conference/default.aspx

Poster Presentation P-10: Synergistic Effect of Successive Administration of TTI-621 (SIRPaFc) and PEGylated Interferon-a2a in a Patient with Sézary Syndrome

Presenter: Dr. Oleg Akilov, University of Pittsburgh

This case study reported local and systemic anti-tumor activity in a Sézary syndrome patient treated with a single intratumoral dose of TTI-621. Administration of PEGylated Interferon-a2a seven days after TTI-621 resulted in decreased leukemic burden and improvements in clinical symptoms. Trillium believes such a reduction is not observed regularly with standard regimens and would not be anticipated following PEGylated Interferon-a2a monotherapy, suggesting a synergistic effect of TTI-621 and PEGylated Interferon-a2a.

“CTCL patients are being treated in both our intratumoral and intravenous trials,” said Dr. Niclas Stiernholm, Trillium’s Chief Executive Officer. “Careful study of the effects of TTI-621 in CTCL patients potentially provides us with a unique opportunity to better understand the mechanism behind TTI-621’s anti-tumor activity and the role of CD47 in the overall immuno-oncology landscape, ultimately leading to targeted indications and combination therapies with sound scientific rationale.”